Mavorixafor

Mavorixafor
Clinical data
Trade namesXolremdi
Other namesX4P-001; AMD-070
AHFS/Drugs.comMultum Consumer Information
License data
Routes of
administration		By mouth
Drug classCXCR4 antagonist
ATC code
  • None
Legal status
Legal status
Identifiers
  • N′-(1H-Benzimidazol-2-ylmethyl)-N′-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H27N5
Molar mass349.482 g·mol−1
3D model (JSmol)
  • C1C[C@@H](C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3
  • InChI=1S/C21H27N5/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25)/t19-/m0/s1
  • Key:WVLHHLRVNDMIAR-IBGZPJMESA-N

Mavorixafor, sold under the brand name Xolremdi, is a medication used for the treatment of WHIM syndrome.[1] It is a CXC chemokine receptor 4 antagonist.[1] It is taken by mouth.[1] It was developed by X4 Pharmaceuticals.

The most frequently reported adverse reactions include thrombocytopenia (low platelet counts), rash, rhinitis (stuffy nose), epistaxis (nosebleed), vomiting, and dizziness.[2]

Mavorixafor was approved for medical use in the United States in April 2024.[1][2][3][4]

  1. ^ a b c d e "Xolremdi- mavorixafor capsule, gelatin coated". DailyMed. 4 June 2024. Retrieved 16 June 2024.
  2. ^ a b "FDA approves first drug for WHIM syndrome, a rare disorder". U.S. Food and Drug Administration (FDA). 29 April 2024. Archived from the original on 29 April 2024. Retrieved 29 April 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ^ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 29 April 2024. Archived from the original on 30 April 2024. Retrieved 30 April 2024.
  4. ^ "X4 Pharmaceuticals Announces FDA Approval of Xolremdi (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome" (Press release). X4 Pharmaceuticals. 29 April 2024. Archived from the original on 29 April 2024. Retrieved 29 April 2024 – via GlobeNewswire.